ALF 2024 Final program
Thursday, November 7th, 2024
08:15-08:30 OPENING CEREMONY
08:30-10:00 SESSION 1: Screening in hepatology
Chairs: Grgurevic I, Skladany L
Current non-invasive screening algorithms and their limitations | Tsochatzis EA
Screening for liver disease in general population | Graupera I / Gines P
Is it the time for personalized screening of HCC? | Frankova S
Screening for a rare liver disease: Gaucher disease | Smolic R
Panel discussion: can we improve early detection of liver disease? | Mikolasevic I
10:00-10:30 Coffee break
10:30-12:00 SESSION 2: Portal hypertension
Chairs: Filipec-Kanizaj T, Frankova S
TIPS for bleeding esophageal varices | Garcia-Pagan JC
The role and limitations of HVPG | Procopet B
HVPG in the real life: 10-year cirrhosis registry study | Skladany L
Kidney injury in advanced liver cirrhosis | Sperl I
Further decompensation of liver cirrhosis | Grgurevic I
12:00-13:00 Lunch
13:00-14:15 SESSION 3: Screening in hepatology
Chairs: Jarcuska P, Virović Jukić L
HCV therapy in different real world patient populations | Flisiak R
HBV - what's new in the guidelines in 2024 | Jaroszewicz J
Reactivation of viral hepatitis in patients on immunosupressive tx | Hrstic I
Infection Model for HCV Vaccine Development | Hunyadi B14:15-14:30 Coffee break
14:30-15:45 SESSION 3: Screening in hepatology
Chairs: Jarcuska P, Virović Jukić L
PBC treatment: current status and perspectives | Milic S
New steps forward in the prevention and treatment of decompensated cirrhosis and ACLF and the significance of biomarkers | Papp M
Cardiovascular risk in Liver Disease | Drazilova S
Plasma exchange for acute-on-chronic liver failure | Volkanovska A
15:45-16:00 FINAL REMARKS AND CLOSURE